Status:
UNKNOWN
Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions:
Hormone Receptor-positive Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Leuprorelin, a LHRH agonist, acts as a potent inhibitor of gonadotropin secretion and is commonly used for the treatment of hormone-responsive prostate cancer, premenopausal HR+ breast cancer, endomet...
Detailed Description
Background: There are some differences in the age of onset of breast cancer, histopathological types, and treatment methods between Asians and non-Asians. Incidence peaks at age 40-50 in Asian women,...
Eligibility Criteria
Inclusion
- age≥18 years;
- Tumor that expressed ER or progesterone receptor in at least 10% of the cells, as assessed by immunohistochemical testing
- T1 to T3, any N, and M0, according to the TNM classification
- Any type of breast surgical procedure
- Any type of preoperative and/or postoperative adjuvant chemotherapy prior to enrollment
- Capable of receiving the study drug within 12 weeks after surgery or after postoperative chemotherapy completion prior to enrollment
- Eastern Cooperative Oncology Group performance status of Grade 0 or 1
Exclusion
- Bilateral oophorectomy or ovarian irradiation
- No use of other OFS drugs
Key Trial Info
Start Date :
May 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04891731
Start Date
May 1 2021
End Date
September 1 2023
Last Update
May 18 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.